Shanghai Bide Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (August 29, 2024)
Special Report on the Deposit and Use of Funds Raised for the Semi-Annual Year of 2024
Opinions of Haitong Securities Co., Ltd. on the verification of the use of idle funds by Shanghai Bide Pharmaceutical Technology Co., Ltd. for cash management
Announcement of Resolutions of the Seventh Meeting of the Second Board of Supervisors
Bide Pharmaceutical: Semi-Annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Value Return” Action Plan
Legal Opinion on the Shareholding Increase of BiDe Pharmaceutical's Actual Controller, Chairman and General Manager.
Special Explanation on Financial Issues Relevant to the Inquiry Letter on 2023 Annual Report of BiDe Pharmaceutical by Zhonghui Certified Public Accountants
Haitong Securities Co., Ltd.'s verification opinion on the differential dividend of Shanghai Bide Pharmaceutical Technology Co., Ltd.
Announcement on holding the results briefing for the first quarter of 2023 and 2024
Independent Director Candidate Statements and Commitments
Independent Director Nominee Statements and Commitments
Nomination Committee's review opinions on independent director candidates
Haitong Securities Co., Ltd. report on the 2023 continuous supervision site inspection report of Shanghai Bide Pharmaceutical Technology Co., Ltd.
Haitong Securities Co., Ltd.'s 2023 Continuous Supervision Annual Follow-up Report on Shanghai Bide Pharmaceutical Technology Co., Ltd.
Shanghai Bide Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (April 26, 2024)
2023 Audit Report
Special review instructions for non-operating capital occupation and other related capital transactions
Independent Director's Debriefing Report-Liu Zhichang
2023 Internal Control Audit Report
2023 Accounting Firm Performance Assessment Report
No Data
No Data